However, data to fully report the efficacy and incidence of drug-induced pneumonitis for molecular-targeted therapies targeting driver gene mutations other than EGFR in NSCLC patients with comorbid IP remain insufficient. This evidence concerns the gene EGFR and non-small cell lung carcinoma.